NCT07032935 The Effect of Virtual Reality Glasses on Vital Signs and State Anxiety in Patients Undergoing Coronary Angiography
| NCT ID | NCT07032935 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Kutahya Health Sciences University |
| Condition | Coronary Angiography (CAG) |
| Study Type | INTERVENTIONAL |
| Enrollment | 100 participants |
| Start Date | 2026-05-30 |
| Primary Completion | 2026-11-15 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 100 participants in total. It began in 2026-05-30 with a primary completion date of 2026-11-15.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Virtual reality (VR) is an effective, safe, and non-pharmacological intervention for reducing anxiety, with strong scientific evidence and no known adverse effects. By providing relaxation and distraction, VR suppresses sympathetic nervous system activity while enhancing parasympathetic activity, thereby promoting a relaxation response. VR immerses patients in a virtual environment, diverting attention from stressful clinical settings and reducing anxiety, fear, and worry. This psychological effect is accompanied by favorable physiological responses, including reductions in blood pressure (BP), heart rate (HR), and respiratory rate (RR), as well as improvements in peripheral oxygen saturation (SpO₂). Previous studies have demonstrated the effectiveness of VR in reducing preoperative anxiety across various clinical settings. For example, VR has been shown to decrease anxiety in adult patients undergoing sternotomy, reduce anxiety before maxillofacial surgery, and provide anxiety relief comparable to progressive muscle relaxation during arthroscopic knee surgery. These findings support the use of VR as an accessible and cost-effective intervention for anxiety management. In recent years, artificial intelligence (AI) has emerged as a valuable tool for analyzing complex clinical data and identifying patterns that may not be detected using conventional statistical methods. AI-supported analyses can integrate physiological measurements with patient-reported outcomes to provide a more comprehensive evaluation of intervention effectiveness. Despite growing evidence supporting VR interventions, no previous study has evaluated the effectiveness of VR in patients undergoing coronary angiography using both conventional outcome measures and AI-supported analytical approaches. Therefore, this randomized controlled study aims to investigate the effects of a VR intervention on state anxiety and vital signs in patients undergoing coronary angiography while applying AI-supported analyses to improve the evaluation of intervention effectiveness.
Eligibility Criteria
Inclusion Criteria: Patients who will undergo coronary angiography or pacemaker implantation, Not to receive sedation during the procedure, Written and verbal acceptance to participate in the study, * Are over 18 years of age, * Do not have any psychiatric illness, * Do not have any vision, hearing or perception problems, * Are at least a primary school graduate, * Do not have any disorder/disease affecting decision-making ability (dementia, psychological disorder, etc.) * Volunteer to participate in the study, * Are open to communication and cooperation. Exclusion Criteria: * Patients who receive sedation, patients who cannot communicate, patients with visual or hearing impairments, and individuals who do not agree to participate in the research will be included.
Contact & Investigator
BURCU NAL
PRINCIPAL INVESTIGATOR
Kütahya Health Science University
Frequently Asked Questions
Who can join the NCT07032935 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 70 Years, studying Coronary Angiography (CAG). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07032935 currently recruiting?
Yes, NCT07032935 is actively recruiting participants. Contact the research team at burcu.nal@ksbu.edu.tr for enrollment information.
Where is the NCT07032935 trial being conducted?
This trial is being conducted at Merkez, Turkey (Türkiye), Kütahya, Turkey (Türkiye).
Who is sponsoring the NCT07032935 clinical trial?
NCT07032935 is sponsored by Kutahya Health Sciences University. The principal investigator is BURCU NAL at Kütahya Health Science University. The trial plans to enroll 100 participants.